Gluten epitopes that are toxic for celiac disease, are not recognized by immunological assays in our Gluten Friendly™ flour.
With these findings, that showed a drastic reduction of cross-reactivity with antibodies, we involved Casa Sollievo della Sofferenza Hospital at San Giovanni Rotondo in Italy. We conducted our first clinical trial to test the effects of Gluten Friendly flour on celiac patients. The 50 volunteers ate Gluten Friendly™ bread daily for three months.
Our study was made possible with funding by the European Union’s Horizon 2020 SME Programme and our Industrial Partner, Casillo Group. A great team effort that makes us proud.
We thank all the volunteers for their time and enthusiasm. We are excited to share some of their stories.